Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

HEBON

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.

Original languageEnglish (US)
Article number112
JournalBreast Cancer Research
Volume18
Issue number1
DOIs
StatePublished - Nov 11 2016

Fingerprint

Mutation
Progesterone Receptors
Estrogen Receptors
Ovarian Neoplasms
Breast Neoplasms
Loss of Heterozygosity
Tumor Biomarkers
Phenotype
Neoplasms

Keywords

  • BRCA1
  • BRCA2
  • Hereditary breast and ovarian cancer
  • Transheterozygosity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. / HEBON.

In: Breast Cancer Research, Vol. 18, No. 1, 112, 11.11.2016.

Research output: Contribution to journalArticle

@article{9084a1b673a748d3851b6664e62103ee,
title = "Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women",
abstract = "Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 {\%}). {"}Cases{"} were defined as TH, and {"}controls{"} were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 {"}controls{"} carried a BRCA1 mutation found in the TH {"}case{"}. Matched SH2 {"}controls{"} carried a BRCA2 mutation found in the TH {"}case{"}. After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 {\%}) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.",
keywords = "BRCA1, BRCA2, Hereditary breast and ovarian cancer, Transheterozygosity",
author = "HEBON and Rebbeck, {Timothy R.} and Friebel, {Tara M.} and Nandita Mitra and Fei Wan and Stephanie Chen and Andrulis, {Irene L.} and Paraskevi Apostolou and Norbert Arnold and Arun, {Banu K.} and Daniel Barrowdale and Javier Benitez and Raanan Berger and Pascaline Berthet and Ake Borg and Buys, {Saundra S.} and Trinidad Caldes and Jonathan Carter and Jocelyne Chiquette and Claes, {Kathleen B M} and Couch, {Fergus J} and Cezary Cybulski and Daly, {Mary B.} and {de la Hoya}, Miguel and Orland Diez and Domchek, {Susan M.} and Nathanson, {Katherine L.} and Katarzyna Durda and Steve Ellis and Evans, {D. Gareth} and Lenka Foretova and Eitan Friedman and Debra Frost and Ganz, {Patricia A.} and Judy Garber and Gord Glendon and Godwin, {Andrew K.} and Greene, {Mark H.} and Jacek Gronwald and Eric Hahnen and Emily Hallberg and Ute Hamann and Hansen, {Thomas V O} and Imyanitov, {Evgeny N.} and Claudine Isaacs and Anna Jakubowska and Ramunas Janavicius and Katarzyna Jaworska-Bieniek and John, {Esther M.} and Karlan, {Beth Y.} and Bella Kaufman",
year = "2016",
month = "11",
day = "11",
doi = "10.1186/s13058-016-0768-3",
language = "English (US)",
volume = "18",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

AU - HEBON

AU - Rebbeck, Timothy R.

AU - Friebel, Tara M.

AU - Mitra, Nandita

AU - Wan, Fei

AU - Chen, Stephanie

AU - Andrulis, Irene L.

AU - Apostolou, Paraskevi

AU - Arnold, Norbert

AU - Arun, Banu K.

AU - Barrowdale, Daniel

AU - Benitez, Javier

AU - Berger, Raanan

AU - Berthet, Pascaline

AU - Borg, Ake

AU - Buys, Saundra S.

AU - Caldes, Trinidad

AU - Carter, Jonathan

AU - Chiquette, Jocelyne

AU - Claes, Kathleen B M

AU - Couch, Fergus J

AU - Cybulski, Cezary

AU - Daly, Mary B.

AU - de la Hoya, Miguel

AU - Diez, Orland

AU - Domchek, Susan M.

AU - Nathanson, Katherine L.

AU - Durda, Katarzyna

AU - Ellis, Steve

AU - Evans, D. Gareth

AU - Foretova, Lenka

AU - Friedman, Eitan

AU - Frost, Debra

AU - Ganz, Patricia A.

AU - Garber, Judy

AU - Glendon, Gord

AU - Godwin, Andrew K.

AU - Greene, Mark H.

AU - Gronwald, Jacek

AU - Hahnen, Eric

AU - Hallberg, Emily

AU - Hamann, Ute

AU - Hansen, Thomas V O

AU - Imyanitov, Evgeny N.

AU - Isaacs, Claudine

AU - Jakubowska, Anna

AU - Janavicius, Ramunas

AU - Jaworska-Bieniek, Katarzyna

AU - John, Esther M.

AU - Karlan, Beth Y.

AU - Kaufman, Bella

PY - 2016/11/11

Y1 - 2016/11/11

N2 - Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.

AB - Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.

KW - BRCA1

KW - BRCA2

KW - Hereditary breast and ovarian cancer

KW - Transheterozygosity

UR - http://www.scopus.com/inward/record.url?scp=85000995840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000995840&partnerID=8YFLogxK

U2 - 10.1186/s13058-016-0768-3

DO - 10.1186/s13058-016-0768-3

M3 - Article

C2 - 27836010

AN - SCOPUS:85000995840

VL - 18

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - 112

ER -